Physician profile
Erick James Willis
NPI 1912111097
$1,248.55
in general payments reported to CMS, 2019-2025
24 companies · $45.14 in 2025
The $45.14 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $63.62 · 2021: $44.26 · 2022: $196 · 2023: $380 · 2024: $305 · 2025: $45.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $183.84 | 2022-2024 | |
| Tris Pharma INC | $135.88 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $130.92 | 2023-2024 | Azstarys |
| Shield Therapeutics INC | $90.57 | 2023-2024 | Accrufer |
| Glaxosmithkline, LLC. | $82.95 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $81.56 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $69.65 | 2021-2022 | |
| Boston Scientific Corporation | $58.85 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Travere Therapeutics, INC. | $49.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.46 | 2022-2023 | Xifaxan |
| Shire North American Group INC | $42.39 | 2019 | |
| Exeltis, USA INC. | $31.84 | 2023-2025 | Tyblume, Slynd |
| Ironshore Pharmaceuticals INC. | $30.98 | 2019 | |
| Xeris Pharmaceuticals, INC. | $29.54 | 2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $27.71 | 2024 | Injectafer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.37 | 2023 | |
| Astellas Pharma US INC | $19.33 | 2022 | |
| Neos Therapeutics, LP | $19.07 | 2020 | |
| Sanofi Pasteur INC. | $18.33 | 2019 | |
| Organon LLC | $15.97 | 2025 | Nexplanon |
| Sage Therapeutics, LLC | $15.40 | 2024 | |
| Abbvie INC. | $15.09 | 2023 | Vraylar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.73 | 2020 | |
| Exact Sciences Corporation | $14.18 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.